Welcome to the dedicated Spotlight On Policy page, your central resource for curated, expert-driven coverage of pharmaceutical and health system policy across the United States, the United Kingdom, Europe, and the wider global landscape. US Policy updates Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform News Are RSV shots next in line for restrictions in the US? After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots. News Antibiotic is first approval in FDA national priority scheme FDA approves its first 'national priority' drug – a version of the widely used antibiotic Augmentin XR – in double-quick time. News FDA set to raise bar for clinical trials of CAR-T therapies The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials. more EU Policy updates Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG. News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer. News Approvals extend use of Roche, AbbVie drugs in lymphoma Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly. Market Access Beyond the Bill: how do we make medicines affordable without... Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future. more UK Policy updates News UK confirms lower clawback rate for NHS medicines The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step." News Slow recruitment still hitting UK trials, says pharma Despite efforts to improve the environment for UK clinical trials, the sector is still facing headwinds like low recruitment rates and rising costs. News UK and US agree zero tariffs on pharma – with price rises A deal between the UK and the US will maintain tariffs on imports into the US at 0%, but prices of medicines used by the NHS will go up. News Real-world trial of Lilly's tirzepatide starts in UK A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK. more
Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform
News Are RSV shots next in line for restrictions in the US? After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.
News Antibiotic is first approval in FDA national priority scheme FDA approves its first 'national priority' drug – a version of the widely used antibiotic Augmentin XR – in double-quick time.
News FDA set to raise bar for clinical trials of CAR-T therapies The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.
Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG.
News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.
News Approvals extend use of Roche, AbbVie drugs in lymphoma Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.
Market Access Beyond the Bill: how do we make medicines affordable without... Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.
News UK confirms lower clawback rate for NHS medicines The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."
News Slow recruitment still hitting UK trials, says pharma Despite efforts to improve the environment for UK clinical trials, the sector is still facing headwinds like low recruitment rates and rising costs.
News UK and US agree zero tariffs on pharma – with price rises A deal between the UK and the US will maintain tariffs on imports into the US at 0%, but prices of medicines used by the NHS will go up.
News Real-world trial of Lilly's tirzepatide starts in UK A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.
